How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,610 results for

Anti-Retroviral Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Individualized Antiretroviral Therapy

in the Safety and Efficacy of First Line Antiretroviral Therapy in Patients With HIV Infection Actual Study Start Date : October 5, 2017 Estimated Primary Completion Date : December 15, 2019 Estimated Study Completion Date : December 31, 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Pharmacological Adequation (PA) Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug (...) for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents

2017 Clinical Trials

142. Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

(Inserm-ANRS) Study Details Study Description Go to Brief Summary: The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV infected patients with controlled viral load for at least 12 months and stable antiretroviral treatment since 4 months. Condition or disease Intervention/treatment Phase HIV Infections Drug: Treatment (...) Estimated Study Completion Date : December 2020 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 4 days / 7 Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks Drug: Treatment discontinuation • Receiving tritherapy. Allowed treatment drugs are : nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine protease inhibitors : lopinavir

2017 Clinical Trials

143. Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)

, a detriment on pIA compared to triple therapy and, therefore, would worsen the patients' long-term prognosis. Condition or disease Intervention/treatment Phase HIV Infections Drug: Continue with triple therapy Drug: Switch to DTG + 3TC Drug: Switch to DRV/cobicistat + 3TC Phase 4 Detailed Description: Primary Outcome Measures: to evaluate the changes in the CD4/CD8 ratio, immune activation and other immunologic parameters at 48 weeks after switching to dual therapy based on dolutegravir plus emtricitabine (...) Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual) Actual Study Start Date : June 1, 2017 Estimated Primary Completion Date : June 1, 2019 Estimated Study Completion Date : June 1, 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Triple therapy To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide

2017 Clinical Trials

144. Adoptive Cell Therapy Across Cancer Diagnoses

Marie Svane, Herlev Hospital Study Details Study Description Go to Brief Summary: This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses. Condition or disease Intervention/treatment Phase Cancer Biological: Autologous tumor-infiltrating lymphocytes Drug: Ipilimumab Drug: Nivolumab Drug: proleukin Drug: Cyclophosphamide Drug: Fludara Phase 1 Phase 2 Detailed Description (...) (IL-2). Checkpoint inhibition to support the anti-tumor activity of TILs is currently under extensive investigation in several other trials worldwide. Thus, lymphodepletion and IL-2 stimulation are well-established as supportive therapy and already an integrated part of current ACT protocols and while checkpoint inhibition is a new addition at CCIT; internationally other centers have ongoing comparable trials. Drug-based immunotherapy in the form of checkpoint inhibitors (anti-PD-1 and anti-CTLA-4

2017 Clinical Trials

145. Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma

Actual Study Start Date : October 1, 2015 Estimated Primary Completion Date : August 10, 2019 Estimated Study Completion Date : August 10, 2019 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Valganciclovir Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8. Drug: Valganciclovir (...) of combined Antiretroviral Therapy (cART). The objective of this study is to evaluate the presence of IRIS and its attributable mortality in patients with HIV and severe KS with the use of Ganciclovir or the prodrug Valganciclovir prior to the initiation of cART compared with the standard management of immediate cART initiation. Condition or disease Intervention/treatment Phase Kaposi Sarcoma Human Immunodeficiency Virus Immune Reconstitution Syndrome Drug: Valganciclovir Drug: Antiretroviral Combinations

2017 Clinical Trials

146. The Effectiveness of SMS in Improving Antiretroviral Medication Adherence Among Adolescents Living With HIV in Nigeria

number #57473 ( Other Grant/Funding Number: MERCK SHARP & DOHME CORP. ) First Posted: January 9, 2018 Last Update Posted: December 27, 2018 Last Verified: December 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Dr. Olumide ABIODUN, Babcock University: Adherence Adolescents Antiretroviral therapy HIV Nigeria (...) Randomized controlled trial Short message services Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents

2017 Clinical Trials

147. Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized, Open-label, Multi-part Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers Actual Study Start Date : January 31, 2017 Actual Primary Completion Date : June 28, 2017 Actual Study Completion Date : June 28, 2017 Resource links provided by the National Library of Medicine related topics: available (...) ] changes in physical examinations during and after study drug administration [ Time Frame: Day 1 to Day 22 ] changes in clinical laboratory results during and after study drug administration [ Time Frame: Day 1 to Day 22 ] changes in electrocardiogram results during and after study drug administration [ Time Frame: Day 1 to Day 22 ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor

2017 Clinical Trials

148. Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

(MRI) within 2 months of study enrollment Allergy or intolerance to nelfinavir or selected PD1/PDL1 immune checkpoint inhibitor Patients requiring steroids or other immunosuppressive therapy; low-dose or topical steroids are allowable if being used as replacement therapy Patients receiving anti-retroviral therapy or other agents that are contra-indicated with nelfinavir due to drug-drug interactions Pregnant or lactating patients Prior radiation that precludes delivery of hypofractionated (...) Recurrent Renal Cell Carcinoma Stage IV Cutaneous Melanoma AJCC v6 and v7 Stage IV Non-Small Cell Lung Cancer AJCC v7 Stage IV Renal Cell Cancer AJCC v7 Drug: Atezolizumab Radiation: Hypofractionated Radiation Therapy Other: Laboratory Biomarker Analysis Drug: Nelfinavir Mesylate Biological: Nivolumab Biological: Pembrolizumab Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. Safety, tolerability and preliminary assessment of overall response rate (ORR) to combination of hypofractionated radiotherapy

2017 Clinical Trials

149. HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

screening visit reveals HSIL on biopsy, may be re-screened one time, >= 2 months after therapy Resident in the area and willing to attend up to 7 clinic visits for a 36-month period at the Virology Research Clinic (VRC) Sexually active women of child-bearing potential must be willing to use effective contraception through month 7 of the study If HIV positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollment Ability to give informed consent Willingness to sign (...) HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2017 Clinical Trials

150. Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Product: No Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Tenofovir Emtricitabine Efavirenz Dolutegravir Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Anti-Retroviral Agents Antiviral (...) -Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants Actual Study Start Date : December 12, 2017 Estimated Primary Completion Date : July 31, 2020 Estimated Study Completion Date : July 31, 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Arm 1: Maternal DTG+FTC/TAF Mothers will receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide

2017 Clinical Trials

151. Nutritional Therapy Improves Dyslipidemia in HIV Infected Teenagers With Antiretroviral Treatment

) Sharing Statement: Plan to Share IPD: Undecided Keywords provided by Hospital de Clinicas de Porto Alegre: HIV / AIDS Dyslipidemia Adolescents Nutritional Therapy Additional relevant MeSH terms: Layout table for MeSH terms Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents (...) : To evaluate the effect of nutritional therapy in dyslipidemic adolescents living with HIV / AIDS in antiretroviral therapy. Method: This is a randomized clinical trial with young people 13-19 years in outpatient treatment in a general hospital to present dyslipidemia. The intervention group received nutritional counseling for 12 weeks and weekly flights to nutritional counseling. The control group received standard care consisting of medical care. Demographic, clinical, nutritional variables, food surveys

2017 Clinical Trials

152. Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents (...) , 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks. Other Name: Ribasphere® Outcome Measures Go to Primary Outcome Measures : Proportion of Participants With Sustained Virologic Response 12 weeks after discontinuation of Therapy (SVR12) [ Time Frame: Posttreatment Week 12 ] SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration Secondary Outcome Measures : Proportion of participants permanently discontinuing study drug(s) due to an adverse event (AE

2017 Clinical Trials

153. Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

after the last day of study drug administration Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 20 Years (...) will be allowed Others as specified in detailed protocol. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03020095 Sponsors and Collaborators Ascletis Pharmaceuticals Co., Ltd. Investigators Layout table for investigator information Study Director: Huoling

2017 Clinical Trials

154. Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

System Diseases Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections RNA Virus Infections Ribavirin Ritonavir Peginterferon alfa-2a Interferon-alpha Lactams Antimetabolites Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-Infective Agents HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Anti-HIV Agents Anti-Retroviral Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Immunologic Factors Physiological Effects of Drugs Anti-Bacterial (...) (bodyweight<75/≥75 kg) Other Name: Ribasphere® Outcome Measures Go to Primary Outcome Measures : Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment [ Time Frame: 24 weeks ] SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends

2017 Clinical Trials

155. Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB

chemotherapy. We aimed to assess whether immunotherapy with Interleukin(IL)-2 enhanced the clinical and immune effects of treatment on MDR-TB patients.We performed a multicentre prospective cohort study extend all over Jiangsu province in China. Two groups were generated based on the adjunctive rhIL-2 therapy during 24 months regiman. Bacteriological and imaging data were followed during 24 months with cure rates analysed. Condition or disease Intervention/treatment Phase MDR TB Drug: RhIL-2 Phase 2 Phase (...) Investigators Layout table for investigator information Principal Investigator: Hong Wang, PH.D the First Affiliated Hospital of Nanjing Medical University, Nanjing, China More Information Go to Layout table for additonal information Responsible Party: The First Affiliated Hospital with Nanjing Medical University ClinicalTrials.gov Identifier: Other Study ID Numbers: rhIL-2 Therapy ON MDR-TB First Posted: March 3, 2017 Last Update Posted: March 3, 2017 Last Verified: September 2009 Layout table

2017 Clinical Trials

156. Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients

cirrhosis in haemodialysis patients. Condition or disease Intervention/treatment Phase Chronic Hepatitis c Drug: Ombitasvir, Paritaprevir and Ritonavir Phase 2 Detailed Description: The aim of this study is; To evaluate the efficacy and safety of ombitasvir, paritaprevir, and ritonavir based therapy for chronic hepatitis C with or without compensated cirrhosis in HCV treatment naïve patients receiving long-term haemodialysis through assessment of: The proportion of patients with a sustained virological (...) response (HCV RNA <25 IU/mL) 12 weeks after the last dose of study drug (SVR12). To determine withdrawal rate related to side effects and /or adverse effects for patients receiving at least 1 dose of the study medication. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 40 participants Intervention Model: Single Group Assignment Intervention Model Description: Prospective, cohort, open label trial Masking: None (Open Label

2017 Clinical Trials

157. Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy

, Tenofovir Disoproxil Fumarate Drug Combination Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents (...) at the clinical point of care. Our rapid assay will help clinicians identify patients in need of more adherence counseling, which when implemented will prevent HIV acquisition, emergence of drug resistant virus, and unnecessary ART regimen switching—measures that will improve national HIV programs and help preserve the global supply of an effective HIV medication. Condition or disease Intervention/treatment Phase Hiv Drug: Truvada Not Applicable Study Design Go to Layout table for study information Study Type

2017 Clinical Trials

158. Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Institute Collaborators: UNITAID National Institute of Allergy and Infectious Diseases (NIAID) National Health and Medical Research Council, Australia ViiV Healthcare Janssen Pharmaceutica Information provided by (Responsible Party): Kirby Institute Study Details Study Description Go to Brief Summary: D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir pharmaco (...) With Pharmaco-enhanced Darunavir Versus Dolutegravir With Predetermined Nucleosides Versus Recommended Standard of Care ART Regimens in Patients With HIV-1 Infection Failing First Line Therapy. Actual Study Start Date : November 23, 2017 Estimated Primary Completion Date : December 31, 2020 Estimated Study Completion Date : December 28, 2021 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator

2017 Clinical Trials

159. Off-therapy Response After Stopping Entecavir or Tenofovir

disease, alcoholic liver disease, toxin exposures) Evidence of drug abuse (including excessive alcohol consumption). Prophylactic use of ETV or TDF therapy. (for cancer chemotherapy or post-transplant immunosuppressive therapy prophylaxis) Patients who have clinical evidence of liver cirrhosis. Inability or unwillingness to provide informed consent or abide by the requirements of the study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study (...) Chung-Ho Memorial Hospital Information provided by (Responsible Party): Kaohsiung Medical University Chung-Ho Memorial Hospital Study Details Study Description Go to Brief Summary: Pegylated-interferon (Peg-IFN) α-2a, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are current recommended first-line antiviral therapies for chronic hepatitis B (CHB). Compared with Peg-IFN therapy, nucleot(s)ide analogue (NUC) therapy has the advantages of having a potent antiviral effect, and good tolerance

2017 Clinical Trials

160. Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants

Manasyan, University of Alabama at Birmingham: EID HIV Early Infant Diagnosis Point of Care Infant HIV Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents (...) Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>